Document is current
Any future updates will be listed below
-
Authors
Eapen, Renu S. http://orcid.org/0000-0003-0590-6234
Williams, Scott G.
Macdonald, Sean
Keam, Simon P.
Lawrentschuk, Nathan
Au, Lewis
Hofman, Michael S. http://orcid.org/0000-0001-8622-159X
Murphy, Declan G. http://orcid.org/0000-0002-7500-5899
Neeson, Paul J. http://orcid.org/0000-0002-2729-5887
- License Information
-
More Information
Article History
Accepted: 21 June 2024
First Online: 7 August 2024
Competing interests
: R.S.E. is supported through the Prostate Cancer Foundation (PCF) Michael and Lori Milken Young Investigator Award. She reports honorarium for advisory board and speaker activity from Janssen, Bayer, Astellas, AstraZeneca, Ipsen, MSD, MDI and Amgen. L.A. reports honorarium from Bristol Myers Squibb (BMS), Eisai and Ipsen. M.S.H. reports philanthropic/government grant support from PCF funded by CANICA Oslo Norway, Peter MacCallum Foundation, Medical Research Future Fund, NHMRC Investigator Grant, Movember, US Department of Defence and the Prostate Cancer Foundation of Australia. D.G.M. reports reimbursement for advisory board and speaker activity from Janssen, Bayer, AstraZeneca, Ipsen and Ferring. P.J.N. reports research funding from BMS, Roche Genentech, MSD, Crispr therapeutics and Allergan. There was no impact on this work from other interests.
